MILWAUKEE, April 15, 2024 /PRNewswire/ — Ademi LLP is investigating Encore (Nasdaq: WIRE) for possible breaches of fiduciary duty and other violations of law in its transaction with Prysmian. Click here to learn how to join the https://www.ademilaw.com/case/encore-wire-corporation or…
Month: April 2024
CITYCON OYJ Stock Exchange Release 15 April 2024 at 10:30 hrs HELSINKI, April 15, 2024 /PRNewswire/ — The Board of Directors of Citycon Oyj has resolved to launch a new stock option plan and restricted share unit plan directed to the Chief Executive Officer. The aim is to align the…
TreeFrog Therapeutics berichtet über die erste Bioproduktion einer Zelltherapie für Parkinson-Krankheit in einem skalierbaren Bioreaktor1 BORDEAUX, Frankreich, 15. April 2024 /PRNewswire/ — TreeFrog Therapeutics, ein Unternehmen zur Entwicklung von Zelltherapien mit seinem führenden…
– TreeFrog presenta datos de su programa de terapia celular contra el Parkinson en la reunión anual de la Academia Americana de Neurología – TreeFrog Therapeutics informa de la primera bioproducción de una terapia celular para la enfermedad de Parkinson en un biorreactor escalable1…
OpenText brings together customers, partners and industry luminaries to explore the transformative power of AI as the force multiplier for human potential LONDON, April 15, 2024 /PRNewswire/ — OpenText™ (NASDAQ: OTEX), (TSX: OTEX), the information company, today began its OpenText World…
LOS ANGELES, April 15, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against InMode Ltd. (“InMode” or “the Company”) (NASDAQ: INMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of…
TreeFrog Therapeutics reports on the first bioproduction of a cell therapy for Parkinson’s Disease in a scalable bioreactor1 BORDEAUX, France, April 15, 2024 /PRNewswire/ — TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson’s Disease is…
TreeFrog Therapeutics fait état de la première bioproduction d’une thérapie cellulaire pour la maladie de Parkinson dans un bioréacteur évolutif1 BORDEAUX, France, 15 avril 2024 /PRNewswire/ — TreeFrog Therapeutics, une société de développement de thérapies cellulaires dont le programme…
LOS ANGELES, April 15, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amplitude, Inc. (“Amplitude” or “the Company”) (NASDAQ: AMPL) for violations of §§10(b) and 20(a) of the Securities Exchange…
TreeFrog Therapeutics reports on the first bioproduction of a cell therapy for Parkinson’s Disease in a scalable bioreactor1 BORDEAUX, France, April 15, 2024 /PRNewswire/ — TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson’s Disease is…